CSL Net Change in Intangible Assets 2017-2024 | CSLLY

CSL net change in intangible assets for the twelve months ending December 31, 2024 was $0M, a 0% increase year-over-year.

  • CSL annual net change in intangible assets for 2024 was $-0.409B, a 11.85% decline from 2023.
  • CSL annual net change in intangible assets for 2023 was $-0.464B, a 174.56% increase from 2022.
  • CSL annual net change in intangible assets for 2022 was $-0.169B, a 64.1% decline from 2021.

CSL Net Change in Intangible Assets 2017-2024 | CSLLY

  • CSL annual net change in intangible assets for 2024 was $-0.409B, a 11.85% decline from 2023.
  • CSL annual net change in intangible assets for 2023 was $-0.464B, a 174.56% increase from 2022.
  • CSL annual net change in intangible assets for 2022 was $-0.169B, a 64.1% decline from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$229.3B
Amgen (AMGN)$159.6B
Gilead Sciences (GILD)$140.8B
Vertex Pharmaceuticals (VRTX)$118.7B
Bristol Myers Squibb (BMY)$90B
GSK (GSK)$76.7B
Regeneron Pharmaceuticals (REGN)$60.3B
Alnylam Pharmaceuticals (ALNY)$52.4B
Argenex SE (ARGX)$41.2B
BioNTech SE (BNTX)$25.8B
Royalty Pharma (RPRX)$20.9B
Insmed (INSM)$20.6B
Biogen (BIIB)$19.3B
Illumina (ILMN)$15B
Incyte (INCY)$14.8B
Genmab (GNMSF)$14.7B
Genmab (GMAB)$14B
BioMarin Pharmaceutical (BMRN)$11.1B
QIAGEN (QGEN)$11.1B
Moderna (MRNA)$10.7B
Ascendis Pharma (ASND)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Exelixis (EXEL)$10B
Exact Sciences (EXAS)$9B
Verona Pharma American Depositary Share (VRNA)$9B
Bio-Techne Corp (TECH)$8.6B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$7.7B
Halozyme Therapeutics (HALO)$7.3B
Legend Biotech (LEGN)$7.1B